Covid-19 Research

Original Article

The State of Cervical Cancer Screening and HPV Vaccination in Africa: In the Advent of Advanced Health Care

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Original Article
Subject Medicine Group
OCLC 9331581432
Emmanuel Kwateng Drokow, Clement Yaw Effah, Clement Agboyibor, Gloria Selorm Akpabla and Kai Sun*
Issue: Volume2-Issue10
Pages: 985-998
Received: 2021-09-22
Accepted: 2021-10-20
Published: 2021-10-29

Abstract

Cervical cancer if not detected and treated promptly can be lethal to females. In several advanced nations, the relevance of coordinated screening services has been implemented. Nevertheless, most developing nations have not implemented a nationwide screening and vaccination programme accessible to all women owing to inadequate screening and vaccination services coupled with vaccine scepticism, misconception concerning vaccination, and lack of awareness are causing an upsurge in Africa's cervical cancer cases. Cervical cancer could be greatly reduced if comprehensive screening services and HPV vaccination are implemented. In this review, we discussed the cervical cancer incidence in Africa, factors influencing the high rate of cervical cancer in Africa, screening and HPV vaccination programs and the potential intervention and recommendations to reduce the incident and mortality rates of cervical cancer in Africa. Also, we highlighted the disadvantages and advantages of widely accessible screening tests in Africa.

FullText HTML FullText PDF DOI: 10.37871/jbres1341 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2021 Drokow EK, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Drokow EK, Effah CY, Agboyibor C, Akpabla GS, Sun K. The State of Cervical Cancer Screening and HPV Vaccination in Africa: In the Advent of Advanced Health Care. J Biomed Res Environ Sci. 2021 Oct 29; 2(10): 985-998. doi: 10.37871/jbres1341, Article ID: JBRES1341, Available at: https://www.jelsciences.com/articles/jbres1341.pdf

Subject area(s)

OncologyCancer

University/Institute

Zhengzhou University

References

  1. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):553-60. doi: 10.1158/1055-9965.EPI-12-1406. PMID: 23549399; PMCID: PMC3711590.
  2. Waggoner SE. Cervical cancer. Lancet. 2003 Jun 28;361(9376):2217-25. doi: 10.1016/S0140-6736(03)13778-6. PMID: 12842378.
  3. Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, Dillner J, Törnberg S. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008 May 7;100(9):622-9. doi: 10.1093/jnci/djn099. Epub 2008 Apr 29. PMID: 18445828.
  4. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. 6. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2014.
  5. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003 Feb 6;348(6):489-90. doi: 10.1056/NEJMp020178. PMID: 12571255.
  6. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007 Jun 1;195(11):1582-9. doi: 10.1086/516784. Epub 2007 Apr 16. PMID: 17471427.
  7. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005 Jun 20;337(1):76-84. doi: 10.1016/j.virol.2005.04.002. PMID: 15914222.
  8. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;(31):20-8. PMID: 12807941.
  9. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006 Sep 1;119(5):1108-24. doi: 10.1002/ijc.21953. PMID: 16570271.
  10. Plummer M, Peto J, Franceschi S; International Collaboration of Epidemiological Studies of Cervical Cancer. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer. 2012 Jun 1;130(11):2638-44. doi: 10.1002/ijc.26250. Epub 2011 Aug 12. PMID: 21702036; PMCID: PMC3982220.
  11. Sato S, Itamochi H. Secondary Prevention of Uterine Cervical Cancer. Cervical Cancer: Screening, Treatment and Prevention-Universal Protocols for Ultimate Control. 2018 May;16:59.
  12. Basu P, Mittal S, Bhadra Vale D, Chami Kharaji Y. Secondary Prevention of Cervical Cancer. International Agency for Research on Cancer. 2017:1-13.
  13. Aggarwal P. Cervical cancer: Can it be prevented? World J Clin Oncol. 2014 Oct 10;5(4):775-80. doi: 10.5306/wjco.v5.i4.775. PMID: 25302177; PMCID: PMC4129540.
  14. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PMID: 25651787.
  15. Jeronimo J, Castle PE, Temin S, Denny L, Gupta V, Kim JJ, Luciani S, Murokora D, Ngoma T, Qiao Y, Quinn M, Sankaranarayanan R, Sasieni P, Schmeler KM, Shastri SS. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. J Glob Oncol. 2016 Oct 12;3(5):635-657. doi: 10.1200/JGO.2016.006577. PMID: 29094101; PMCID: PMC5646891.
  16. Arrossi S, Temin S, Garland S, Eckert LO, Bhatla N, Castellsagué X, Alkaff SE, Felder T, Hammouda D, Konno R, Lopes G, Mugisha E, Murillo R, Scarinci IC, Stanley M, Tsu V, Wheeler CM, Adewole IF, de Sanjosé S. Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline. J Glob Oncol. 2017 Mar 17;3(5):611-634. doi: 10.1200/JGO.2016.008151. PMID: 29094100; PMCID: PMC5646902.
  17. de Villiers EM. Heterogeneity of the human papillomavirus group. J Virol. 1989 Nov;63(11):4898-903. doi: 10.1128/JVI.63.11.4898-4903.1989. PMID: 2552162; PMCID: PMC251129.
  18. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009 Apr 10;84(15):118-31. English, French. PMID: 19360985.
  19. WHO and UNICEF. Progress towards global immunization goals - 2011. Geneva: World Health Organization. 2012;35.
  20. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med. 2007 May 10;356(19):1908-10. doi: 10.1056/NEJMp078053. PMID: 17494923.
  21. GAVI welcomes lower prices for life-saving vaccines. June 6, 2011.
  22. GAVI injects new life into HPV vaccine rollout. Lancet. 2013 May 18;381(9879):1688. doi: 10.1016/S0140-6736(13)61058-2. PMID: 23683613.
  23. GAVI, Millions of girls in developing countries to be protected against cervical cancer thanks to new HPV vaccine deals-2013- Press releases-News-Library-GAVI Alliance. 2013.
  24. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F. Chapter 15: HPV vaccine use in the developing world. Vaccine. 2006 Aug 31;24 Suppl 3:S3/132-9. doi: 10.1016/j.vaccine.2006.05.128. PMID: 16950000.
  25. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ. 2012 Aug 1;90(8):623-8. doi: 10.2471/BLT.11.097253. Epub 2012 May 23. PMID: 22893746; PMCID: PMC3417784.
  26. Binagwaho A, Wagner CM, Nutt CT. HPV vaccine in Rwanda: different disease, same double standard. Lancet. 2011 Dec 3;378(9807):1916. doi: 10.1016/S0140-6736(11)61837-0. PMID: 22137840.
  27. Ouedraogo N, Müller O, Jahn A, Gerhardus A. Human papillomavirus vaccination in Africa. Lancet. 2011 Jul 23;378(9788):315-6. doi: 10.1016/S0140-6736(11)61164-1. PMID: 21784261.
  28. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, Janmohamed A, Kumakech E, Mosqueira NR, Nguyen NQ, Paul P, Tang Y, Minh TH, Uttekar BP, Jumaan AO. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011 Nov 1;89(11):821-830B. doi: 10.2471/BLT.11.089862. Epub 2011 Sep 1. PMID: 22084528; PMCID: PMC3209730.
  29. Moodley I, Tathiah N, Mubaiwa V, Denny L. High uptake of Gardasil vaccine among 9 - 12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa. S Afr Med J. 2013 May;103(5):318-21. doi: 10.7196/samj.6414. PMID: 23971122.
  30. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012 May 23;12:370. doi: 10.1186/1471-2458-12-370. PMID: 22621342; PMCID: PMC3419135.
  31. Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjosé S, Wight D, Changalucha J, Hayes R. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis. 2012 Sep 1;206(5):678-86. doi: 10.1093/infdis/jis407. Epub 2012 Jun 18. PMID: 22711908; PMCID: PMC3414230.
  32. Ayissi CA, Wamai RG, Oduwo GO, Perlman S, Welty E, Welty T, Manga S, Ogembo JG. Awareness, acceptability and uptake of human papilloma virus vaccine among Cameroonian school-attending female adolescents. J Community Health. 2012 Dec;37(6):1127-35. doi: 10.1007/s10900-012-9554-z. PMID: 22426995.
  33. De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine. 2013 Dec 29;31 Suppl 5(0 5):F32-46. doi: 10.1016/j.vaccine.2012.07.092. PMID: 24331746; PMCID: PMC4144870.
  34. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020 Jul;70(4):313. doi: 10.3322/caac.21609. Epub 2020 Apr 6. Erratum for: CA Cancer J Clin. 2018 Nov;68(6):394-424. PMID: 32767693.
  35. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6. PMID: 30350310.
  36. The Cancer Atlas. 2021.
  37. https://bit.ly/3nbttYB
  38. Cunningham MS, Davison C, Aronson KJ. HPV vaccine acceptability in Africa: a systematic review. Prev Med. 2014 Dec;69:274-9. doi: 10.1016/j.ypmed.2014.08.035. Epub 2014 Oct 24. PMID: 25451327.
  39. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6. doi: 10.1016/j.vaccine.2006.05.120. Epub 2006 Jun 23. PMID: 16950001.
  40. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006 Aug 31;24 Suppl 3:S3/178-86. doi: 10.1016/j.vaccine.2006.05.116. PMID: 16950005.
  41. Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine. 2013 Aug 20;31(37):3811-7. doi: 10.1016/j.vaccine.2013.06.016. Epub 2013 Jun 15. PMID: 23777956; PMCID: PMC3763375.
  42. Ebosse Y. Mama Fouda authorizes a vaccine that kills. Le Soir Hebd. Yaounde, Cameroon: The Evening Weekly; 2010.
  43. Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. Lancet. 2010 Aug 21;376(9741):572-3. doi: 10.1016/S0140-6736(10)60881-1. PMID: 20728739.
  44. Khan KS, Ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD's guidance for carrying out or commissioning reviews. NHS Centre for Reviews and Dissemination. 2001.
  45. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019 Jan 12;393(10167):169-182. doi: 10.1016/S0140-6736(18)32470-X. PMID: 30638582.
  46. Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: A review. World J Gastrointest Surg. 2016 Jan 27;8(1):41-51. doi: 10.4240/wjgs.v8.i1.41. PMID: 26843912; PMCID: PMC4724586.
  47. Näsman A, Du J, Dalianis T. A global epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine. J Intern Med. 2020 Feb;287(2):134-152. doi: 10.1111/joim.13010. Epub 2019 Dec 9. PMID: 31733108.
  48. Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017 Apr;40(2):80-85. Epub 2017 Apr 3. PMID: 28368072.
  49. Tulay P, Serakinci N. The role of human papillomaviruses in cancer progression. J Cancer Metastasis Treat. 2016;2:201-213.
  50. Shah A, Malik A, Garg A, Mair M, Nair S, Chaturvedi P. Oral sex and human papilloma virus-related head and neck squamous cell cancer: a review of the literature. Postgrad Med J. 2017 Nov;93(1105):704-709. doi: 10.1136/postgradmedj-2016-134603. Epub 2017 Aug 4. PMID: 28778951.
  51. Yeo-Teh NSL, Ito Y, Jha S. High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int J Mol Sci. 2018 Jun 8;19(6):1706. doi: 10.3390/ijms19061706. PMID: 29890655; PMCID: PMC6032416.
  52. Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, Cullen M, Boland JF, Wentzensen N, Nelson CW, Raine-Bennett T, Chen Z, Bass S, Song L, Yang Q, Steinberg M, Burdett L, Dean M, Roberson D, Mitchell J, Lorey T, Franceschi S, Castle PE, Walker J, Zuna R, Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C, Burk RD, Schiffman M. HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell. 2017 Sep 7;170(6):1164-1174.e6. doi: 10.1016/j.cell.2017.08.001. PMID: 28886384; PMCID: PMC5674785.
  53. Doeberitz Mv, Vinokurova S. Host factors in HPV-related carcinogenesis: cellular mechanisms controlling HPV infections. Arch Med Res. 2009 Aug;40(6):435-42. doi: 10.1016/j.arcmed.2009.06.002. Epub 2009 Sep 5. PMID: 19853183.
  54. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006 May;110(5):525-41. doi: 10.1042/CS20050369. PMID: 16597322.
  55. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine. 2012 Nov 20;30 Suppl 5:F55-70. doi: 10.1016/j.vaccine.2012.06.083. PMID: 23199966.
  56. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20458-63. doi: 10.1073/pnas.0908502106. Epub 2009 Nov 17. PMID: 19920181; PMCID: PMC2787115.
  57. Reuschenbach M, Waterboer T, Wallin KL, Einenkel J, Dillner J, Hamsikova E, Eschenbach D, Zimmer H, Heilig B, Kopitz J, Pawlita M, Doeberitz Mv, Wentzensen N. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer. 2008 Dec 1;123(11):2626-31. doi: 10.1002/ijc.23837. PMID: 18785210.
  58. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 2004 Aug 1;64(15):5449-55. doi: 10.1158/0008-5472.CAN-04-0831. PMID: 15289354.
  59. Fischer M, Uxa S, Stanko C, Magin TM, Engeland K. Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway. Sci Rep. 2017 Jun 1;7(1):2603. doi: 10.1038/s41598-017-02831-9. PMID: 28572607; PMCID: PMC5453983.
  60. Khan A, Junaid M, Kaushik AC, Ali A, Ali SS, Mehmood A, Wei DQ. Computational identification, characterization and validation of potential antigenic peptide vaccines from hrHPVs E6 proteins using immunoinformatics and computational systems biology approaches. PLoS One. 2018 May 1;13(5):e0196484. doi: 10.1371/journal.pone.0196484. PMID: 29715318; PMCID: PMC5929558.
  61. Biedermann K, Dandachi N, Trattner M, Vogl G, Doppelmayr H, Moré E, Staudach A, Dietze O, Hauser-Kronberger C. Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue. J Clin Microbiol. 2004 Aug;42(8):3758-65. doi: 10.1128/JCM.42.8.3758-3765.2004. PMID: 15297527; PMCID: PMC497646.
  62. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005 Apr;6(4):204. doi: 10.1016/s1470-2045(05)70086-3. PMID: 15830458.
  63. Yuan J, Ni G, Wang T, Mounsey K, Cavezza S, Pan X, Liu X. Genital warts treatment: Beyond imiquimod. Hum Vaccin Immunother. 2018 Jul 3;14(7):1815-1819. doi: 10.1080/21645515.2018.1445947. Epub 2018 Apr 9. PMID: 29505317; PMCID: PMC6067868.
  64. Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CL. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):101-6. PMID: 11219765.
  65. Castellsagué X, Ghaffari A, Daniel RW, Bosch FX, Muñoz N, Shah KV. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis. 1997 Aug;176(2):353-61. doi: 10.1086/514052. PMID: 9237700.
  66. Omone OM, Kozlovszky M. HPV and Cervical Cancer Screening Awareness: A Case-control Study in Nigeria. In 2020 IEEE 24th International Conference on Intelligent Engineering Systems (INES). IEEE. 2020;145-152.
  67. Banister CE, Liu C, Pirisi L, Creek KE, Buckhaults PJ. Identification and characterization of HPV-independent cervical cancers. Oncotarget. 2017 Feb 21;8(8):13375-13386. doi: 10.18632/oncotarget.14533. PMID: 28077784; PMCID: PMC5355105.
  68. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15;141(4):664-670. doi: 10.1002/ijc.30716. Epub 2017 Jun 8. PMID: 28369882; PMCID: PMC5520228.
  69. Deivendran S, Marzook KH, Radhakrishna Pillai M. The role of inflammation in cervical cancer. Adv Exp Med Biol. 2014;816:377-99. doi: 10.1007/978-3-0348-0837-8_15. PMID: 24818731.
  70. Dugué PA, Rebolj M, Garred P, Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther. 2013 Jan;13(1):29-42. doi: 10.1586/era.12.159. PMID: 23259425.
  71. Ebrahimi S, Soltani A, Hashemy SI. Oxidative stress in cervical cancer pathogenesis and resistance to therapy. J Cell Biochem. 2018 Nov 13. doi: 10.1002/jcb.28007. Epub ahead of print. PMID: 30426530.
  72. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15. PMID: 20952254.
  73. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009 Mar 15;199(6):805-14. doi: 10.1086/597071. PMID: 19199546.
  74. Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Physician. 2016 May;62(5):399-402. Epub 2016 May 12. PMID: 27255620; PMCID: PMC4865336.
  75. Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, Burger EA, Martin D, Nguyen DTN, Bénard É, Sy S, Regan C, Drolet M, Gingras G, Laprise JF, Torode J, Smith MA, Fidarova E, Trapani D, Bray F, Ilbawi A, Broutet N, Hutubessy R. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020 Feb 22;395(10224):591-603. doi: 10.1016/S0140-6736(20)30157-4. Epub 2020 Jan 30. PMID: 32007142; PMCID: PMC7043006.
  76. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020 Jul 16;8(3):391. doi: 10.3390/vaccines8030391. PMID: 32708759; PMCID: PMC7565290.
  77. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Jul;4(7):e453-63. doi: 10.1016/S2214-109X(16)30099-7. Erratum in: Lancet Glob Health. 2017 Jul;5(7):e662. PMID: 27340003.
  78. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15;141(4):664-670. doi: 10.1002/ijc.30716. Epub 2017 Jun 8. PMID: 28369882; PMCID: PMC5520228.
  79. Sabeena S, Bhat PV, Kamath V, Arunkumar G. Global human papilloma virus vaccine implementation: An update. J Obstet Gynaecol Res. 2018 Jun;44(6):989-997. doi: 10.1111/jog.13634. Epub 2018 Mar 8. PMID: 29517117.
  80. Ährlund-Richter A, Cheng L, Hu YOO, Svensson M, Pennhag AAL, Ursu RG, Haeggblom L, Grün N, Ramqvist T, Engstrand L, Dalianis T, Du J. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine. Front Cell Infect Microbiol. 2019 Mar 20;9:59. doi: 10.3389/fcimb.2019.00059. PMID: 30949454; PMCID: PMC6435486.
  81. Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen OE, Kjaer SK, Ferenczy A, Kurman RJ, Ronnett BM, Stoler MH, Bautista OM, Moeller E, Ritter M, Shields C, Luxembourg A. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019 Jul;154(1):110-117. doi: 10.1016/j.ygyno.2019.03.253. Epub 2019 Apr 11. PMID: 30982556.
  82. Bhatla N, Nene BM, Joshi S, Esmy PO, Poli URR, Joshi G, Verma Y, Zomawia E, Pimple S, Prabhu PR, Basu P, Muwonge R, Hingmire S, Sauvaget C, Lucas E, Pawlita M, Gheit T, Jayant K, Malvi SG, Siddiqi M, Michel A, Butt J, Sankaran S, Kannan TPRA, Varghese R, Divate U, Willhauck-Fleckenstein M, Waterboer T, Müller M, Sehr P, Kriplani A, Mishra G, Jadhav R, Thorat R, Tommasino M, Pillai MR, Sankaranarayanan R; Indian HPV vaccine study group. Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India. Papillomavirus Res. 2018 Jun;5:163-171. doi: 10.1016/j.pvr.2018.03.008. Epub 2018 Mar 22. PMID: 29578097; PMCID: PMC6047463.
  83. Sonawane K, Nyitray AG, Nemutlu GS, Swartz MD, Chhatwal J, Deshmukh AA. Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women. JAMA Netw Open. 2019 Dec 2;2(12):e1918571. doi: 10.1001/jamanetworkopen.2019.18571. PMID: 31880792; PMCID: PMC6986697.
  84. Kjaer SK, Nygård M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, Tryggvadottir L, Joshi A, Das R, Saah AJ. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. Clin Infect Dis. 2018 Jan 18;66(3):339-345. doi: 10.1093/cid/cix797. PMID: 29029053.
  85. Haque A, Kouriba B, Aïssatou N, Pant A. Eliminating Cervical Cancer in Mali and Senegal, Two Sub-Saharan Countries: Insights and Optimizing Solutions. Vaccines (Basel). 2020 Apr 14;8(2):181. doi: 10.3390/vaccines8020181. PMID: 32295116; PMCID: PMC7349839.
  86. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine. 2013 Dec 29;31 Suppl 5:F47-52. doi: 10.1016/j.vaccine.2012.06.066. PMID: 24331747.
  87. ACCP. Visual screening approaches: Promising alterative screening strategies. Cervical Cancer Prevention Fact Sheet. October 2002.
  88. Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, Nouhou H, Sakande B, Wesley R, Somanathan T, Sharma A, Shastri S, Basu P. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer. 2008 Jul 1;123(1):153-60. doi: 10.1002/ijc.23489. PMID: 18404671.
  89. Ghosh P, Gandhi G, Kochhar PK, Zutshi V, Batra S. Visual inspection of cervix with Lugol's iodine for early detection of premalignant & malignant lesions of cervix. Indian J Med Res. 2012 Aug;136(2):265-71. PMID: 22960894; PMCID: PMC3461739.
  90. Sahasrabuddhe VV, Gravitt PE, Dunn ST, Brown D, Allen RA, Eby YJ, Smith K, Zuna RE, Zhang RR, Gold MA, Schiffman M, Walker JL, Castle PE, Wentzensen N. Comparison of human papillomavirus detections in urine, vulvar, and cervical samples from women attending a colposcopy clinic. J Clin Microbiol. 2014 Jan;52(1):187-92. doi: 10.1128/JCM.01623-13. Epub 2013 Nov 6. PMID: 24197879; PMCID: PMC3911475.
  91. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4. PMID: 31812369; PMCID: PMC7025157.
  92. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
  93. Odida M, Schmauz R, Lwanga SK. Grade of malignancy of cervical cancer in regions of Uganda with varying malarial endemicity. Int J Cancer. 2002 Jun 10;99(5):737-41. doi: 10.1002/ijc.10384. PMID: 12115509.
  94. Adoch W, Garimoi CO, Scott SE, Okeny GG, Moodley J, Komakech H, Walter FM, Mwaka AD. Knowledge of cervical cancer risk factors and symptoms among women in a refugee settlement: a cross-sectional study in northern Uganda. Confl Health. 2020 Dec 3;14(1):85. doi: 10.1186/s13031-020-00328-3. PMID: 33292345; PMCID: PMC7713037.
  95. Mboumba Bouassa RS, Prazuck T, Lethu T, Jenabian MA, Meye JF, Bélec L. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease. Expert Rev Anti Infect Ther. 2017 Jun;15(6):613-627. doi: 10.1080/14787210.2017.1322902. Epub 2017 May 5. PMID: 28440679.
  96. Moelle U, Mathewos A, Aynalem A, Wondemagegnehu T, Yonas B, Begoihn M, Addissie A, Unverzagt S, Jemal A, Thomssen C, Vordermark D, Kantelhardt EJ. Cervical Cancer in Ethiopia: The Effect of Adherence to Radiotherapy on Survival. Oncologist. 2018 Sep;23(9):1024-1032. doi: 10.1634/theoncologist.2017-0271. Epub 2018 Mar 22. PMID: 29567823; PMCID: PMC6192604.
  97. Ononogbu U, Almujtaba M, Modibbo F, Lawal I, Offiong R, Olaniyan O, Dakum P, Spiegelman D, Blattner W, Adebamowo C. Cervical cancer risk factors among HIV-infected Nigerian women. BMC Public Health. 2013 Jun 14;13:582. doi: 10.1186/1471-2458-13-582. PMID: 23767681; PMCID: PMC3728111.
  98. Anorlu RI. Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters. 2008 Nov;16(32):41-9. doi: 10.1016/S0968-8080(08)32415-X. PMID: 19027621.
  99. Bayo S, Bosch FX, de Sanjosé S, Muñoz N, Combita AL, Coursaget P, Diaz M, Dolo A, van den Brule AJ, Meijer CJ. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol. 2002 Feb;31(1):202-9. doi: 10.1093/ije/31.1.202. PMID: 11914322.
  100. Muwonge R, Ngo Mbus L, Ngoma T, Gombe Mbalawa C, Dolo A, da Ganda Manuel M, Nouhou H, Nacoulma M, Mwaiselage J, Koulibaly M, Bayo S, Nsonde Malanda J, De Vuyst H, Herrero R, Sankaranarayanan R, Keita N; IARC Multicentre Study Group on Cervical Cancer Early Detection. Socio-demographic and reproductive determinants of cervical neoplasia in seven sub-Sahara African countries. Cancer Causes Control. 2016 Dec;27(12):1437-1446. doi: 10.1007/s10552-016-0823-5. Epub 2016 Nov 7. PMID: 27822586.
  101. Kasa AS, Tesfaye TD, Temesgen WA. Knowledge, attitude and practice towards cervical cancer among women in Finote Selam city administration, West Gojjam Zone, Amhara Region, North West Ethiopia, 2017. Afr Health Sci. 2018 Sep;18(3):623-636. doi: 10.4314/ahs.v18i3.20. PMID: 30602995; PMCID: PMC6307012.
  102. Rocha JW. Culture and its influence on an increase of cervical cancer cases in Angola. Brazilian Journal of Oncology. 2020;16:1-5.
  103. de Abreu AL, Malaguti N, Souza RP, Uchimura NS, Ferreira ÉC, Pereira MW, Carvalho MD, Pelloso SM, Bonini MG, Gimenes F, Consolaro ME. Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co-infections on the risk of high-grade squamous intraepithelial cervical lesion. Am J Cancer Res. 2016 Jun 1;6(6):1371-83. PMID: 27429850; PMCID: PMC4937739.
  104. Kharsany AB, Karim QA. HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS J. 2016 Apr 8;10:34-48. doi: 10.2174/1874613601610010034. PMID: 27347270; PMCID: PMC4893541.
  105. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach (second edition)-annex 10, WHO clinical staging of HIV disease in adults, adolescents and children. June 2016.
  106. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014 May 15;28(8):1193-202. doi: 10.1097/QAD.0000000000000243. PMID: 24556869; PMCID: PMC4004637.
  107. Joint United Nations Programme on HIV/AIDS. HIV estimates with uncertainty bounds. July 2020;1990-2019.
  108. Kelly HA, Chikandiwa A, Sawadogo B, Gilham C, Michelow P, Lompo OG, Omar T, Zan S, Magooa P, Segondy M, Nagot N, Meda N, Delany-Moretlwe S, Mayaud P; HARP Study Group. Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study. PLoS Med. 2021 Mar 4;18(3):e1003528. doi: 10.1371/journal.pmed.1003528. PMID: 33661957; PMCID: PMC7971880.
  109. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, McAllister DA, Gottlieb SL, Klug SJ, Winkler AS, Bray F, Baggaley R, Clifford GM, Broutet N, Dalal S. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021 Feb;9(2):e161-e169. doi: 10.1016/S2214-109X(20)30459-9. Epub 2020 Nov 16. Erratum in: Lancet Glob Health. 2021 Feb;9(2):e119. PMID: 33212031; PMCID: PMC7815633.
  110. Taku O, Mbulawa ZZA, Phohlo K, Garcia-Jardon M, Businge CB, Williamson AL. Distribution of Human Papillomavirus (HPV) Genotypes in HIV-Negative and HIV-Positive Women with Cervical Intraepithelial Lesions in the Eastern Cape Province, South Africa. Viruses. 2021 Feb 11;13(2):280. doi: 10.3390/v13020280. PMID: 33670231; PMCID: PMC7916956.
  111. Lekoane KMB, Kuupiel D, Mashamba-Thompson TP, Ginindza TG. The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: scoping review. Syst Rev. 2020 Apr 22;9(1):88. doi: 10.1186/s13643-020-01354-1. PMID: 32321580; PMCID: PMC7178989.
  112. Chambuso RS, Shadrack S, Lidenge SJ, Mwakibete N, Medeiros RM. Influence of HIV/AIDS on Cervical Cancer: A Retrospective Study From Tanzania. J Glob Oncol. 2016 Jun 1;3(1):72-78. doi: 10.1200/JGO.2015.002964. PMID: 28717744; PMCID: PMC5493231.
  113. Reddy D, Njala J, Stocker P, Schooley A, Flores M, Tseng CH, Pfaff C, Jansen P, Mitsuyasu RT, Hoffman RM. High-risk human papillomavirus in HIV-infected women undergoing cervical cancer screening in Lilongwe, Malawi: a pilot study. Int J STD AIDS. 2015 May;26(6):379-87. doi: 10.1177/0956462414539149. Epub 2014 Jun 13. PMID: 24928579; PMCID: PMC4363075.
  114. Wu ES, Urban RR, Krantz EM, Mugisha NM, Nakisige C, Schwartz SM, Gray HJ, Casper C. The association between HIV infection and cervical cancer presentation and survival in Uganda. Gynecol Oncol Rep. 2019 Nov 19;31:100516. doi: 10.1016/j.gore.2019.100516. PMID: 31886403; PMCID: PMC6921151.
  115. Gichangi PB, Bwayo J, Estambale B, De Vuyst H, Ojwang S, Rogo K, Abwao H, Temmerman M. Impact of HIV infection on invasive cervical cancer in Kenyan women. AIDS. 2003 Sep 5;17(13):1963-8. doi: 10.1097/00002030-200309050-00015. PMID: 12960829.
  116. World Health Organization. Working Together for Health: The World Health Report 2006; World Health Organization: Geneva, Switzerland, 2018.
  117. Ruddies F, Gizaw M, Teka B, Thies S, Wienke A, Kaufmann AM, Abebe T, Addissie A, Kantelhardt EJ. Cervical cancer screening in rural Ethiopia: a cross- sectional knowledge, attitude and practice study. BMC Cancer. 2020 Jun 17;20(1):563. doi: 10.1186/s12885-020-07060-4. PMID: 32552740; PMCID: PMC7298871.
  118. Moucheraud C, Kawale P, Kafwafwa S, Bastani R, Hoffman RM. "It is big because it's ruining the lives of many people in Malawi": Women's attitudes and beliefs about cervical cancer. Prev Med Rep. 2020 Apr 8;18:101093. doi: 10.1016/j.pmedr.2020.101093. PMID: 32322461; PMCID: PMC7168763.
  119. Nyamambi E, Murendo C, Sibanda N, Mazinyane S. Knowledge, attitudes and barriers of cervical cancer screening among women in Chegutu rural district of Zimbabwe. Cogent Social Sciences. 2020;6(1):1766784.
  120. Drokow EK, Zi L, Han Q, Effah CY, Agboyibor C, Sasu E, Akpabla GS, Foli F, Sun K. Awareness of Cervical Cancer and Attitude Toward Human Papillomavirus and Its Vaccine Among Ghanaians. Front Oncol. 2020 Sep 8;10:1651. doi: 10.3389/fonc.2020.01651. PMID: 33014828; PMCID: PMC7506130.
  121. Olubodun T, Odukoya OO, Balogun MR. Knowledge, attitude and practice of cervical cancer prevention, among women residing in an urban slum in Lagos, South West, Nigeria. Pan Afr Med J. 2019 Mar 18;32:130. doi: 10.11604/pamj.2019.32.130.14432. PMID: 31223418; PMCID: PMC6561126.
  122. Kimondo FC, Kajoka HD, Mwantake MR, Amour C, Mboya IB. Knowledge, attitude, and practice of cervical cancer screening among women living with HIV in the Kilimanjaro region, northern Tanzania. Cancer Rep (Hoboken). 2021 Mar 19:e1374. doi: 10.1002/cnr2.1374. Epub ahead of print. PMID: 33739611.
  123. Adewumi K, Nishimura H, Oketch SY, Adsul P, Huchko M. Barriers and Facilitators to Cervical Cancer Screening in Western Kenya: a Qualitative Study. J Cancer Educ. 2021 Jan 7. doi: 10.1007/s13187-020-01928-6. Epub ahead of print. PMID: 33411253.
  124. Georges K, Armel Herve NK, Simo Richard T, Jeremie MA, Charlette N. Knowledge and behavior of women on cervical cancer in the northern region of Cameroon 2. 2017.
  125. Almobarak AO, Elbadawi AA, Elmadhoun WM, Elhoweris MH, Ahmed MH. Knowledge, Attitudes and Practices of Sudanese Women Regarding the Pap Smear Test and Cervical Cancer. Asian Pac J Cancer Prev. 2016;17(2):625-30. doi: 10.7314/apjcp.2016.17.2.625. PMID: 26925654.
  126. Eshete M, Abdulwuhab Atta M, Yeshita HY. Cervical Cancer Screening Acceptance among Women in Dabat District, Northwest Ethiopia, 2017: An Institution-Based Cross-Sectional Study. Obstet Gynecol Int. 2020 Feb 7;2020:2805936. doi: 10.1155/2020/2805936. PMID: 32089698; PMCID: PMC7029298.
  127. Anya SE, Oshi DC, Nwosu SO, Anya AE. Knowledge, attitude, and practice of female health professionals regarding cervical cancer and Pap smear. Niger J Med. 2005 Jul-Sep;14(3):283-6. PMID: 16350698.
  128. Anorlu RI, Orakwue CO, Oyeneyin L, Abudu OO. Late presentation of patients with cervical cancer to a tertiary hospital in Lagos: what is responsible? Eur J Gynaecol Oncol. 2004;25(6):729-32. PMID: 15597852.
  129. Dulla D, Daka D, Wakgari N. Knowledge about cervical cancer screening and its practice among female health care workers in southern Ethiopia: a cross-sectional study. Int J Womens Health. 2017 May 22;9:365-372. doi: 10.2147/IJWH.S132202. PMID: 28579837; PMCID: PMC5446960.
  130. Ifemelumma CC, Anikwe CC, Okorochukwu BC, Onu FA, Obuna JA, Ejikeme BN, Ezeonu OP. Cervical Cancer Screening: Assessment of Perception and Utilization of Services among Health Workers in Low Resource Setting. Int J Reprod Med. 2019 Feb 3;2019:6505482. doi: 10.1155/2019/6505482. PMID: 30854395; PMCID: PMC6377970.
  131. Anorlu RI, Banjo AA, Odoemhum C. Cervical cancer and cervical cancer screening: level of awareness in women attending a primary health care facility in Lagos. Nigeria Postgraduate Medical Journal. 2000;70(1):25-28.
  132. Ayinde OA, Omigbodun AO. Knowledge, attitude and practices related to prevention of cancer of the cervix among female health workers in Ibadan. J Obstet Gynaecol. 2003 Jan;23(1):59-62. doi: 10.1080/0144361021000043272. PMID: 12623487.
  133. Anya SE, Oshi DC, Nwosu SO, Anya AE. Knowledge, attitude, and practice of female health professionals regarding cervical cancer and Pap smear. Niger J Med. 2005 Jul-Sep;14(3):283-6. PMID: 16350698.
  134. Adanu RM, Seffah JD, Duda R, Darko R, Hill A, Anarfi J. Clinic visits and cervical cancer screening in accra. Ghana Med J. 2010 Jun;44(2):59-63. doi: 10.4314/gmj.v44i2.68885. PMID: 21327005; PMCID: PMC2994147.
  135. Awodele O, Adeyomoye AA, Awodele DF, Kwashi V, Awodele IO, Dolapo DC. A study on cervical cancer screening amongst nurses in Lagos University Teaching Hospital, Lagos, Nigeria. J Cancer Educ. 2011 Sep;26(3):497-504. doi: 10.1007/s13187-010-0187-6. PMID: 21222192; PMCID: PMC3161190.
  136. Gebreegziabher M, Asefa NG, Berhe S. Factors affecting the practices of cervical cancer screening among female nurses at public health institutions in Mekelle town, Northern Ethiopia, 2014: a cross-sectional study. Journal of Cancer Research. 2016.
  137. Aswathy S, Quereshi MA, Kurian B, Leelamoni K. Cervical cancer screening: Current knowledge & practice among women in a rural population of Kerala, India. Indian J Med Res. 2012 Aug;136(2):205-10. PMID: 22960886; PMCID: PMC3461731.
  138. Teguete I, Muwonge R, Traore CB, Dolo A, Bayo S, Sankaranarayanan R. Can visual cervical screening be sustained in routine health services? Experience from Mali, Africa. BJOG. 2012 Jan;119(2):220-6. doi: 10.1111/j.1471-0528.2011.03122.x. Epub 2011 Sep 6. PMID: 21895956.
  139. Fall NS, Tamalet C, Diagne N, Fenollar F, Raoult D, Sokhna C, Lagier JC. Feasibility, Acceptability, and Accuracy of Vaginal Self-Sampling for Screening Human Papillomavirus Types in Women from Rural Areas in Senegal. Am J Trop Med Hyg. 2019 Jun;100(6):1552-1555. doi: 10.4269/ajtmh.19-0045. PMID: 30994102; PMCID: PMC6553900.
  140. de la Statistique AN. de la Démographie (ANSD) Sénégal. Sénégal, Calverton, Maryland: ANSD and Macro International, Inc. 2010.
  141. Mboumba Bouassa RS, Gubavu C, Veyer D, Robin L, Gravier A, Hocqueloux L, Prazuck T, Péré H, Bélec L; ANRS ImmiPap Study Group. High Prevalence of Cervical High-Risk Human Papillomavirus Harboring Atypical Genotypes in Human Immunodeficiency Virus -Infected and -Uninfected First-Generation Adult Immigrant Women Originating from Sub-Saharan Africa and Living in France. J Immigr Minor Health. 2021 Apr;23(2):308-319. doi: 10.1007/s10903-020-01074-7. PMID: 32816173; PMCID: PMC7914190.
  142. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S; IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005 Sep 17-23;366(9490):991-8. doi: 10.1016/S0140-6736(05)67069-9. PMID: 16168781.
  143. Piroozmand A, Mostafavi Zadeh SM, Madani A, Soleimani R, Nedaeinia R, Niakan M, Avan A, Manian M, Moradi M, Eftekhar Z. The Association of High Risk Human Papillomaviruses in Patients With Cervical Cancer: An Evidence Based Study on Patients With Squamous Cell Dysplasia or Carcinoma for Evaluation of 23 Human Papilloma Virus Genotypes. Jundishapur J Microbiol. 2016 Feb 17;9(4):e32728. doi: 10.5812/jjm.32728. PMID: 27279992; PMCID: PMC4895315.
  144. Mbulawa ZZ, Coetzee D, Williamson AL. Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status. BMC Infect Dis. 2015 Oct 26;15:459. doi: 10.1186/s12879-015-1181-8. PMID: 26502723; PMCID: PMC4624185.
  145. Tounkara FK, Téguété I, Guédou FA, Keita B, Alary M. Prevalence and Factors Associated With HIV and Sexually Transmitted Infections Among Female Sex Workers in Bamako, Mali. Sex Transm Dis. 2020 Oct;47(10):679-685. doi: 10.1097/OLQ.0000000000001231. PMID: 32932403.
  146. Mbulawa ZZA, van Schalkwyk C, Hu NC, Meiring TL, Barnabas S, Dabee S, Jaspan H, Kriek JM, Jaumdally SZ, Muller E, Bekker LG, Lewis DA, Dietrich J, Gray G, Passmore JS, Williamson AL. High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns. PLoS One. 2018 Jan 2;13(1):e0190166. doi: 10.1371/journal.pone.0190166. PMID: 29293566; PMCID: PMC5749739.
  147. Ogembo RK, Gona PN, Seymour AJ, Park HS, Bain PA, Maranda L, Ogembo JG. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis. PLoS One. 2015 Apr 14;10(4):e0122488. doi: 10.1371/journal.pone.0122488. PMID: 25875167; PMCID: PMC4396854.
  148. Keehn DC, Chamberlain RM, Tibbits M, Kahesa C, Msami K, Soliman AS. Using Key Informants to Evaluate Barriers to Education and Acceptability of the HPV Vaccine in Tanzania: Implications for Cancer Education. J Cancer Educ. 2020 May 26:10.1007/s13187-020-01773-7. doi: 10.1007/s13187-020-01773-7. Epub ahead of print. PMID: 32451878; PMCID: PMC7688505.
  149. Mabeya H, Odunga J, Broeck DV. Mothers of adolescent girls and Human Papilloma Virus (HPV) vaccination in Western Kenya. Pan Afr Med J. 2021 Feb 4;38:126. doi: 10.11604/pamj.2021.38.126.21359. PMID: 33912296; PMCID: PMC8051220.
  150. O'Donovan J, O'Donovan C, Nagraj S. The role of community health workers in cervical cancer screening in low-income and middle-income countries: a systematic scoping review of the literature. BMJ Glob Health. 2019 May 13;4(3):e001452. doi: 10.1136/bmjgh-2019-001452. PMID: 31179040; PMCID: PMC6528769.
  151. Ayoub N, Sunwoo JB, Starmer HM. Implementation of a targeted HPV educational program in a population with HIV. World J Otorhinolaryngol Head Neck Surg. 2019 Feb 23;5(2):105-111. doi: 10.1016/j.wjorl.2018.09.006. PMID: 31334489; PMCID: PMC6617159.
  152. Knaul FM, Bhadelia A, Rodriguez NM, Arreola-Ornelas H, Zimmermann C. The lancet commission on palliative care and pain reliefdfindings, recommendations, and future directions. Lancet Glob Heal. 2018;6.
  153. van der Plas WY, Benjamens S, Kruijff S. The increased need for palliative cancer care in Sub-Saharan Africa. Eur J Surg Oncol. 2020 Jul;46(7):1373-1376. doi: 10.1016/j.ejso.2020.03.212. Epub 2020 Mar 27. PMID: 32265092.
  154. Denny L, Anorlu R. Cervical cancer in Africa. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1434-8. doi: 10.1158/1055-9965.EPI-12-0334. Epub 2012 Jul 17. PMID: 22806169.
  155. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516. PMID: 19339719.
  156. Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010 Oct 20;102(20):1557-67. doi: 10.1093/jnci/djq342. Epub 2010 Sep 30. PMID: 20884893.
  157. Clendinen C, Zhang Y, Warburton RN, Light DW. Manufacturing costs of HPV vaccines for developing countries. Vaccine. 2016 Nov 21;34(48):5984-5989. doi: 10.1016/j.vaccine.2016.09.042. Epub 2016 Oct 19. PMID: 27771183.
  158. Munira SL, Hendriks JT, Atmosukarto II, Friede MH, Carter LM, Butler JRG, Clements ACA. A cost analysis of producing vaccines in developing countries. Vaccine. 2019 Feb 21;37(9):1245-1251. doi: 10.1016/j.vaccine.2018.11.050. Epub 2019 Jan 14. PMID: 30651198.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership